Craig L. Slingluff
Elite in Melanoma

Dr. Craig L. Slingluff

Surgical Oncology
Uva Hospital West The Cancer Ctr, Hospital Drive, 
Charlottesville, VA 
Elite in Melanoma
Uva Hospital West The Cancer Ctr, Hospital Drive, 
Charlottesville, VA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Craig Slingluff is a Surgical Oncologist in Charlottesville, Virginia. Dr. Slingluff is rated as an Elite provider by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Eccrine Porocarcinoma, Neuroendocrine Tumor, and Tissue Biopsy.

His clinical research consists of co-authoring 164 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 114 articles and participated in 8 clinical trials in the study of Melanoma.

Specialties
Surgical Oncology
Licenses
Surgery in VA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Piedmont
  • HMO
  • POS

Locations

Uva Hospital West The Cancer Ctr, Hospital Drive, Charlottesville, VA 22908

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Enhanced Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists in Patients With Melanoma
Enhanced Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists in Patients With Melanoma
Enrollment Status: Completed
Publish Date: July 16, 2024
Intervention Type: Drug
Study Drugs: 6MHP, NeoAg-mBRAF, PolyICLC, CDX-1140
Study Phase: Phase 1/Phase 2
Open Label, Randomized, Phase I/II Study of a Long Peptide Vaccine Plus TLR Agonists for Resected Stage IIb-IV Melanoma. (MEL60)
Open Label, Randomized, Phase I/II Study of a Long Peptide Vaccine Plus TLR Agonists for Resected Stage IIb-IV Melanoma. (MEL60)
Enrollment Status: Completed
Publish Date: February 28, 2024
Intervention Type: Other, Biological
Study Drug: Peptide Vaccine (LPV7) + Tetanus Peptide
Study Phase: Phase 1/Phase 2
A Trial to Evaluate the Immunogenicity and Safety of a Melanoma Helper Peptide Vaccine Plus Novel Adjuvant Combinations (MEL63)
A Trial to Evaluate the Immunogenicity and Safety of a Melanoma Helper Peptide Vaccine Plus Novel Adjuvant Combinations (MEL63)
Enrollment Status: Terminated
Publish Date: October 30, 2023
Intervention Type: Drug, Biological
Study Phase: Phase 1/Phase 2
A Trial to Evaluate the Safety, Immunogenicity, and Clinical Activity of a Helper Peptide Vaccine Plus PD-1 Blockade
A Trial to Evaluate the Safety, Immunogenicity, and Clinical Activity of a Helper Peptide Vaccine Plus PD-1 Blockade
Enrollment Status: Completed
Publish Date: August 25, 2023
Intervention Type: Drug, Biological
Study Phase: Phase 1/Phase 2
Analysis of the Kinetics and Effects of Vemurafenib + Cobimetinib on Intratumoral and Host Immunity in Patients With Advanced BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy
Analysis of the Kinetics and Effects of Vemurafenib + Cobimetinib on Intratumoral and Host Immunity in Patients With Advanced BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy
Enrollment Status: Terminated
Publish Date: February 26, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Pilot Trial of an Indoleamine 2,3, Dioxygenase-1 (IDO1) Inhibitor (INCB024360) Plus a Multipeptide Melanoma Vaccine (MELITAC 12.1) in Patients With Advanced Melanoma
A Phase II Pilot Trial of an Indoleamine 2,3, Dioxygenase-1 (IDO1) Inhibitor (INCB024360) Plus a Multipeptide Melanoma Vaccine (MELITAC 12.1) in Patients With Advanced Melanoma
Enrollment Status: Completed
Publish Date: June 08, 2018
Intervention Type: Biological, Drug
Study Phase: Phase 2
This is an Open-label, Phase II Study of a Vaccine Comprising Melanoma Peptides and a Tetanus Helper Peptide, Administered in GM-CSF-in-adjuvant. Patients Will be Randomized to Receive One of Two Different Vaccine Regimens. Patients Will be Stratified by Stage of Disease (IIB vs. III vs. IV).
This is an Open-label, Phase II Study of a Vaccine Comprising Melanoma Peptides and a Tetanus Helper Peptide, Administered in GM-CSF-in-adjuvant. Patients Will be Randomized to Receive One of Two Different Vaccine Regimens. Patients Will be Stratified by Stage of Disease (IIB vs. III vs. IV).
Enrollment Status: Completed
Publish Date: May 02, 2018
Intervention Type: Biological
Study Phase: Phase 2
View 6 Less Clinical Trials

165 Total Publications

Where You Train Matters: Surgeon-Scientists Disproportionately Trained at Highly Funded Institutions.
Where You Train Matters: Surgeon-Scientists Disproportionately Trained at Highly Funded Institutions.
Journal: Annals of surgery
Published: May 09, 2025
Similar Doctors
Distinguished in Melanoma
Dr. Lynn T. Dengel
Surgical Oncology | General Surgery
Distinguished in Melanoma
Dr. Lynn T. Dengel
Surgical Oncology | General Surgery

University Of Virginia Physicians Group

1240 Lee St, 
Charlottesville, VA 
 (0.1 miles away)
434-924-5191
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lynn Dengel is a Surgical Oncologist and a General Surgeon in Charlottesville, Virginia. Dr. Dengel is rated as an Advanced provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Melanoma, Breast Cancer, Paget Disease of the Breast, Lymphadenectomy, and Mastectomy. Dr. Dengel is currently accepting new patients.

Distinguished in Melanoma
Dr. David M. Rose
General Surgery | Surgical Oncology
Distinguished in Melanoma
Dr. David M. Rose
General Surgery | Surgical Oncology

Virginia Cancer Institute Incorporated

10710 Midlothian Tpke, Suite 138, 
North Chesterfield, VA 
 (61.2 miles away)
804-348-2814
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Rose is a General Surgeon and a Surgical Oncologist in North Chesterfield, Virginia. Dr. Rose is rated as a Distinguished provider by MediFind in the treatment of Melanoma. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Breast Cancer, Pancreatectomy, and Small Bowel Resection. Dr. Rose is currently accepting new patients.

Advanced in Melanoma
Dr. Russell G. Witt
Surgical Oncology | General Surgery
Advanced in Melanoma
Dr. Russell G. Witt
Surgical Oncology | General Surgery

University Of Virginia Physicians Group

1240 Lee St, 
Charlottesville, VA 
 (0.1 miles away)
434-924-5191
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Russell Witt is a Surgical Oncologist and a General Surgeon in Charlottesville, Virginia. Dr. Witt is rated as an Advanced provider by MediFind in the treatment of Melanoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Retroperitoneal Liposarcoma, Melanoma, Lymphadenectomy, and Pancreaticoduodenectomy. Dr. Witt is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Slingluff's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile